Viking Therapeutics at $36.45 after 2% decline – analyst target remains at $93.60
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics closed at $36.45 on July 8, 2026, down 2.02 percent from the previous day ($37.20).
- The RSI stood at 74.67 on July 7, signaling overbought conditions; it was already at 75.36 on June 29.
- Analysts see an average price target of $93.60 (as of July 8, 2026), with 22 of 24 analysts recommending buy.
- VK2809 is undergoing Phase IIb studies for NASH and NAFLD as the lead development candidate.
- Analysts' price target range spans from $83 to $101, with a median of $95.
Viking Therapeutics Inc. (VKTX) recorded a price decline of 2.02 percent on July 8, 2026, closing at $36.45. The daily high reached $37.15, with a low of $35.05. Trading volume amounted to 69,583 shares.
Technical indicators show overbought market conditions
The Relative Strength Index (RSI) reached a value of 74.67 on July 7, 2026 – a level typically considered overbought. The RSI measures the momentum of price movements on a scale of 0 to 100; values above 70 suggest possible overheating. As recently as June 29, the RSI stood at 75.36, while in mid-June it was still in the neutral range around 50.
Recent RSI values at a glance:
- July 7: 74.67
- July 6: 68.02
- June 30: 72.56
- June 29: 75.36
- June 24: 75.03
Analysts see significant upside potential
The average analyst price target stands at $93.60 (as of July 8, 2026), representing upside potential of approximately 157 percent versus the current price. Of 24 surveyed analysts, 22 recommend the stock as a buy, while one recommends hold. There are no sell recommendations.
The price target range spans from $83 (lowest target) to $101 (highest target), with a median of $95. The range demonstrates that despite varying valuations, analysts uniformly expect significant value appreciation potential.
Clinical pipeline focused on metabolic diseases
Viking Therapeutics develops therapies for metabolic and endocrine disorders. The lead development candidate VK2809 is an orally available, tissue- and receptor-selective agonist of thyroid hormone receptor beta (TRβ). The drug is currently undergoing Phase IIb studies for treating non-alcoholic steatohepatitis (NASH) – an advanced form of fatty liver disease – as well as non-alcoholic fatty liver disease (NAFLD).
Additional candidates in the development pipeline:
- VK5211: An oral, non-steroidal selective androgen receptor modulator in Phase II for patients following non-elective hip fracture surgery
- VK0612: Orally available agent for type 2 diabetes, progressing toward Phase IIb studies
- VK0214: Another oral candidate in development
Market environment pressures biotechnology sector
The price decline on July 8 coincided with a weaker overall market. According to current market reports, a pullback in chip stocks dragged major US indices lower, while defensive sectors performed better. Biotechnology stocks often react sensitively to broader market movements, as they are frequently classified as risky growth stocks.
Viking Therapeutics, as a clinical-stage biotechnology company – meaning without approved products or revenue – is particularly dependent on investor sentiment and capital market conditions. Financing ongoing studies and future development phases requires regular access to capital.
Valuation and risk profile
The positive analyst assessment is based on the development pipeline's potential, particularly VK2809 for liver diseases. The market for NASH therapies is considered promising, as currently only limited treatment options exist and disease prevalence is rising.
The risk profile remains typical for a clinical-stage biotechnology company: success depends on positive study results, regulatory approvals, and ultimately market acceptance. Setbacks in clinical trials can lead to significant losses. The currently elevated RSI values suggest that investors have reacted optimistically to the company in recent weeks – the stock has risen significantly since mid-June.